Arrowhead Research Corporation Files to Begin Phase 1 Trial of RNAi Therapeutic ARC-520 Against Chronic Hepatitis B Infection
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it recently filed an application for approval to begin a phase 1 clinical trial of its RNAi-based therapeutic candidate, ARC-520, against chronic hepatitis B virus infection. Pending approval, Arrowhead intends to proceed with a phase 1, randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of ARC-520 in normal adult volunteers.
Help employers find you! Check out all the jobs and post your resume.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it recently filed an application for approval to begin a phase 1 clinical trial of its RNAi-based therapeutic candidate, ARC-520, against chronic hepatitis B virus infection. Pending approval, Arrowhead intends to proceed with a phase 1, randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of ARC-520 in normal adult volunteers.
Help employers find you! Check out all the jobs and post your resume.